Posted by: admin on: December 13, 2011
Compared to other hypoglycemic GLP-1 analogs, injectable liraglutide marketed by Novo Nordisk has reiterated its position as an efficient and safe post prandial glycemic level controller. Here is the study. Team@CMHF